微浸润性宫颈腺癌患者生存率并未因根治性手术而改善
该回顾性分析查询1988至2010年监测、流行病学和最终结果数据库,比较国际妇产科联盟IA1或IA2期宫颈癌患者按术式(局部切除、简单子宫切除或根治性子宫切除)的5年生存率。结果显示,腺癌与鳞癌患者间及腺癌患者不同术式间生存均无统计学差异,腺癌盆腔淋巴结阳性率为0.97%。作者据此认为,微浸润性宫颈病变患者术前规划更保守的术式是合适的。
要点
- 腺癌IA1期5年生存率为97.3%,IA2期为98.3%。
- 腺癌患者局部切除、简单子宫切除与根治性子宫切除间生存无统计学差异。
- 腺癌盆腔淋巴结阳性率为0.97%,主动脉淋巴结阳性率为0。
核心结论
- 按细胞类型或术式比较,患者生存率均无显著差异,提示采用更具侵袭性的手术方式并未改善微浸润性腺癌患者的生存。
- 无论组织学类型,两组淋巴结受累频率均很低,支持所有微浸润性疾病患者总体预后极佳。
- 作者提交这些数据作为证据,认为术前规划更保守的术式是合适的,不仅适用于鳞癌组织学类型或希望保留生育功能的患者,也适用于所有微浸润性宫颈疾病患者。
研究设计与样本
- 回顾性分析,查询监测、流行病学和最终结果数据库1988年至2010年数据,纳入国际妇产科联盟IA1或IA2期宫颈癌女性。
- 按术式(局部切除、简单子宫切除或根治性子宫切除)确定每种细胞类型(鳞癌或腺癌)的5年生存率及淋巴结状态。
- 腺癌患者1567例,鳞癌IA1或IA2期患者5749例。
主要发现
- 腺癌患者IA1期5年生存率为97.3%(95%CI 95.8-98.2%),IA2期为98.3%(95%CI 96.5-99.2%)。
- 鳞癌IA1期5年生存率为96.7%(95%CI 96.0-97.3%),IA2期为95.6%(95%CI 94.4-96.5%)。
- 腺癌IA1期局部切除、子宫切除和根治性子宫切除后生存率分别为96.6%、98.4%和96.5%;IA2期分别为100%、96.9%和99.4%。
- 两种细胞类型患者接受局部切除(P=0.26)、简单子宫切除(P=0.08)或根治性子宫切除(P=0.87)的生存率均无统计学差异。
- 腺癌患者中,0.97%盆腔淋巴结阳性,无主动脉淋巴结阳性,91.85%确认淋巴结阴性;鳞癌患者中,0.72%盆腔淋巴结阳性,0.10%主动脉淋巴结阳性。
关键数值与推荐
- 腺癌患者不同术式间生存比较:局部切除与简单子宫切除P=0.64;局部切除与根治性子宫切除P=0.82;简单子宫切除与根治性子宫切除P=0.70,均无统计学显著差异。
临床怎么用
- 作者认为术前规划更保守的术式是合适的,不仅适用于鳞癌组织学类型或希望保留生育功能的患者,也适用于所有微浸润性宫颈疾病患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment for early-invasive adenocarcinoma of the cervix remains controversial. Although data have shown similar survival rates to those seen with squamous cell carcinoma, conservative options for patients with microinvasive adenocarcinoma have not been as widely accepted. Despite comparable survival outcomes, patients with early-invasive adenocarcinoma are still routinely subjected to more radical surgical techniques than their equivalently staged squamous cell counterparts. OBJECTIVE: The objective of the study was to evaluate how less radical surgery has an impact on 5 year survival in patients with microinvasive adenocarcinoma of the cervix. STUDY DESIGN: The Surveillance, Epidemiology, and End Results database was queried from 1988 through 2010 to perform a retrospective analysis of women with International Federation of Gynecology and Obstetrics stage IA1 or IA2 cervical carcinoma. Five year survival by procedure type (local excision, simple hysterectomy, or radical hysterectomy) was determined for each cell type (squamous or adenocarcinoma), as was lymph node status. RESULTS: Among 1567 patients with cervical adenocarcinoma, 5 year survival was 97.3% (confidence interval, 95.8-98.2%) for stage IA1 disease and 98.3% (confidence interval, 96.5%, 99.2%) for stage IA2. For comparison, the 5-year survival rates for 5,749 patients with stage IAI or lA2 squamous cell carcinoma were 96.7% (confidence interval, 96.0-97.3%) and 95.6% (confidence interval, 94.4-96.5%), respectively. For stage IA1 ACA, survival was 96.6%, 98.4% and 96.5% following excision, hysterectomy and radical hysterectomy, respectively. For stage IA2 ACA, survival rates were 100%, 96.9% and 99.4%, respectively. There was no statistical difference in survival between patients having either cell type undergoing local excision (P = .26), simple hysterectomy (P = .08), or radical hysterectomy (P = .87). We also found no statistically significant difference in survival among patients with adenocarcinoma compared by treatment type (local excision compared with simple hysterectomy [P = .64]; local excision compared with radical hysterectomy [P = .82]; or simple hysterectomy compared with radical hysterectomy [P = .70]). Among patients with adenocarcinoma, 0.97% had positive pelvic lymph nodes, none had positive aortic lymph nodes, and 91.85% had confirmed negative lymph nodes. For squamous cell carcinoma, 0.72% of patients had positive pelvic lymph nodes and 0.10% had positive aortic lymph nodes. CONCLUSION: There was no significant difference in survival when patients were compared by cell type or procedure, suggesting that survival of patients with microinvasive adenocarcinoma is not improved by utilizing more invasive surgical methods. Regardless of histology, the frequency of nodal involvement was very low among both groups, supporting an overall excellent prognosis for all patients with microinvasive disease. We submit these data as evidence that preoperative planning of more conservative techniques is appropriate, not just for those with squamous histology or who desire future fertility, but for all patients with microinvasive cervical disease.
引用
- Bean LM, Ward KK, Plaxe SC, et al. Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery. Am J Obstet Gynecol. 2017. PMID: 28522318. doi:10.1016/j.ajog.2017.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。